- The company has signed the new contract with the biopharmaceutical company based in Pennsylvania, USA, accordingly, Venn Life Sciences, part of Open Orphan Plc will provide SFA Therapeutics assistance in the filing of a European Medicines Agency application for Orphan Drug Designation.
- The company hopes that this agreement will be the first step in a longer-term bonding between the two companies.
- On 18th December 2019, at the time of writing, GMT 08:10 AM, ORPH shares were trading at GBX 5.80, up by 0.15 points or 2.65% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.